Trial Profile
A Multicenter, Open-label, Safety Extension Study with Benralizumab (MEDI-563) for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist (MELTEMI)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jun 2021
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Acronyms MELTEMI
- Sponsors AstraZeneca; AstraZeneca AB
- 19 May 2021 Results assessing safety and efficacy in patients receiving benralizumab up to five years presented at the 117th International Conference of the American Thoracic Society
- 19 May 2021 According to an AstraZeneca media release, Arnaud Bourdin, Head of Pulmonology, Professor of Respiratory Medicine at Arnaud de Villeneuve Hospital, Montpellier, France is a primary trial investigator.
- 19 May 2021 According to an AstraZeneca media release, results from the study have been presented at the American Thoracic Society (ATS) 2021 International Conference.